New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
Why now
Thesis: Diagnostic study supports niche test adoption
Catalyst to watch: Reimbursement and adoption data
Main risk: Small addressable market
Why it matters
Study showing a diagnostic test changed management supports adoption but is single-company clinical news.
Details
FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study showing that its TissueCypher® Barrett's Esophagus Test helped guide...
Sources
- prnewswire · 2026-09-28 11:00 UTC